Discovery - University of Dundee - Online Publications

Library & Learning Centre

Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer

Standard

Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. / Ohotski, J.; Long, J. S.; Orange, C.; Elsberger, B.; Mallon, E.; Doughty, J.; Pyne, S.; Pyne, N. J.; Edwards, J.

In: British Journal of Cancer, Vol. 106, No. 8, 10.04.2012, p. 1453-1459.

Research output: Contribution to journalArticle

Harvard

Ohotski, J, Long, JS, Orange, C, Elsberger, B, Mallon, E, Doughty, J, Pyne, S, Pyne, NJ & Edwards, J 2012, 'Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer' British Journal of Cancer, vol 106, no. 8, pp. 1453-1459., 10.1038/bjc.2012.98

APA

Ohotski, J., Long, J. S., Orange, C., Elsberger, B., Mallon, E., Doughty, J., ... Edwards, J. (2012). Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. British Journal of Cancer, 106(8), 1453-1459. 10.1038/bjc.2012.98

Vancouver

Ohotski J, Long JS, Orange C, Elsberger B, Mallon E, Doughty J et al. Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. British Journal of Cancer. 2012 Apr 10;106(8):1453-1459. Available from: 10.1038/bjc.2012.98

Author

Ohotski, J.; Long, J. S.; Orange, C.; Elsberger, B.; Mallon, E.; Doughty, J.; Pyne, S.; Pyne, N. J.; Edwards, J. / Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer.

In: British Journal of Cancer, Vol. 106, No. 8, 10.04.2012, p. 1453-1459.

Research output: Contribution to journalArticle

Bibtex - Download

@article{cf1f070ece504355aaea3dc7532dd9a8,
title = "Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer",
author = "J. Ohotski and Long, {J. S.} and C. Orange and B. Elsberger and E. Mallon and J. Doughty and S. Pyne and Pyne, {N. J.} and J. Edwards",
year = "2012",
doi = "10.1038/bjc.2012.98",
volume = "106",
number = "8",
pages = "1453--1459",
journal = "British Journal of Cancer",
issn = "0007-0920",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer

A1 - Ohotski,J.

A1 - Long,J. S.

A1 - Orange,C.

A1 - Elsberger,B.

A1 - Mallon,E.

A1 - Doughty,J.

A1 - Pyne,S.

A1 - Pyne,N. J.

A1 - Edwards,J.

AU - Ohotski,J.

AU - Long,J. S.

AU - Orange,C.

AU - Elsberger,B.

AU - Mallon,E.

AU - Doughty,J.

AU - Pyne,S.

AU - Pyne,N. J.

AU - Edwards,J.

PY - 2012/4/10

Y1 - 2012/4/10

N2 - <p>BACKGROUND: We previously reported that sphingosine 1-phosphate receptor 4 (S1P(4)) is expressed and stimulates the ERK-1/2 pathway via a human epidermal growth factor receptor 2 (HER2)-dependent mechanism in oestrogen receptor-negative (ER-) MDA-MB-453 breast cancer cells.</p><p>METHODS: Clinical relevance of S1P(4) and sphingosine kinase 1 (SK1, which catalyses the formation of S1P) was assessed in a cohort of 140 ER- breast tumours by immunohistochemistry (IHC) and the weighted histoscore method. Additional evidence for a functional interaction between S1P(4) and SK1 and between HER2 and SK1 was obtained using MDA-MB-453 cells.</p><p>RESULTS: High S1P(4) expression is associated with shorter disease-free (P = 0.014) and disease-specific survival (P = 0.004), and was independent on multivariate analysis. In addition, patients with tumours that contain high and low levels of SK1 and S1P(4), respectively, have a significantly shorter disease-free survival (P = 0.043) and disease-specific survival (P = 0.033) compared with patients whose tumours contain both low S1P(4) and SK1 levels. In addition, high tumour expression of SK1 was significantly associated with shorter disease-specific survival (P = 0.0001) in patients with HER2-positive tumours. Treatment of MDA-MB-453 cells with the SK1 inhibitor, SKi (2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole) reduced the basal and S1P/S1P(4)-induced activation of ERK-1/2 and altered HER2 trafficking in these cells.</p><p>CONCLUSION: These findings highlight an important role for S1P(4) and SK1 in ER- breast cancer progression. British Journal of Cancer (2012) 106, 1453-1459. doi: 10.1038/bjc.2012.98 www.bjcancer.com Published online 29 March 2012 (C) 2012 Cancer Research UK</p>

AB - <p>BACKGROUND: We previously reported that sphingosine 1-phosphate receptor 4 (S1P(4)) is expressed and stimulates the ERK-1/2 pathway via a human epidermal growth factor receptor 2 (HER2)-dependent mechanism in oestrogen receptor-negative (ER-) MDA-MB-453 breast cancer cells.</p><p>METHODS: Clinical relevance of S1P(4) and sphingosine kinase 1 (SK1, which catalyses the formation of S1P) was assessed in a cohort of 140 ER- breast tumours by immunohistochemistry (IHC) and the weighted histoscore method. Additional evidence for a functional interaction between S1P(4) and SK1 and between HER2 and SK1 was obtained using MDA-MB-453 cells.</p><p>RESULTS: High S1P(4) expression is associated with shorter disease-free (P = 0.014) and disease-specific survival (P = 0.004), and was independent on multivariate analysis. In addition, patients with tumours that contain high and low levels of SK1 and S1P(4), respectively, have a significantly shorter disease-free survival (P = 0.043) and disease-specific survival (P = 0.033) compared with patients whose tumours contain both low S1P(4) and SK1 levels. In addition, high tumour expression of SK1 was significantly associated with shorter disease-specific survival (P = 0.0001) in patients with HER2-positive tumours. Treatment of MDA-MB-453 cells with the SK1 inhibitor, SKi (2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole) reduced the basal and S1P/S1P(4)-induced activation of ERK-1/2 and altered HER2 trafficking in these cells.</p><p>CONCLUSION: These findings highlight an important role for S1P(4) and SK1 in ER- breast cancer progression. British Journal of Cancer (2012) 106, 1453-1459. doi: 10.1038/bjc.2012.98 www.bjcancer.com Published online 29 March 2012 (C) 2012 Cancer Research UK</p>

U2 - 10.1038/bjc.2012.98

DO - 10.1038/bjc.2012.98

M1 - Article

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 8

VL - 106

SP - 1453

EP - 1459

ER -

Documents

Library & Learning Centre

Contact | Accessibility | Policy